Regeneron Down 15.5% Year to Date: How to Play the Stock?

Zacks12-13

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%. The stock has underperformed the sector and the S&P 500 Index during ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491537198?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","is_english":true,"pubTime":"2024-12-13 22:09","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2491537198","market":"us","top_or_hot":-1,"title":"Regeneron Down 15.5% Year to Date: How to Play the Stock?","media":"Zacks","content":"<div>\n<p>Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.\nThe stock has underperformed the sector and the S&P 500 Index during ...</p>\n\n<a href=\"https://finance.yahoo.com/news/regeneron-down-15-5-date-140900718.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Down 15.5% Year to Date: How to Play the Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Down 15.5% Year to Date: How to Play the Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-13 22:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/regeneron-down-15-5-date-140900718.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.\nThe stock has underperformed the sector and the S&P 500 Index during ...</p>\n\n<a href=\"https://finance.yahoo.com/news/regeneron-down-15-5-date-140900718.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://finance.yahoo.com/news/regeneron-down-15-5-date-140900718.html","article_id":"2491537198","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491537198","pubTimestamp":1734098940,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.Regeneron has a collaboration agreement with Bayer BAYRY for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea’s sales outside the United States.REGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma  or R/R diffuse large B-cell lymphoma after two","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G.","BK4588":"碎股","SNY":"赛诺菲安万特","LU0058720904.USD":"联博国际健康护理基金A","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","03165":"华夏欧优股对冲","BK4094":"服装零售","RHHBY":"罗氏控股","LU0882574055.USD":"富达全球健康医疗A ACC","BK4585":"ETF&股票定投概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4530":"医药外包概念","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","CRL":"查尔斯河","FL":"富乐客","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4121":"生命科学工具和服务","BK4139":"生物科技","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4007":"制药","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","REGN":"再生元制药公司","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"Regeneron今年迄今下跌15.5%：如何玩转该股？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":1,"SNY":1,"RHHBY":1,"FL":1,"CRL":1,"REGN":0.9,"03165":0.6},"content_text":"Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.\nThe stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.\nRegeneron Underperforms Industry, Sector & S&P 500\nImage Source: Zacks Investment Research\nEylea Sales Decline Hampers REGN's Ophthalmology Unit\nEylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.\nHowever, Eylea’s sales have been under pressure due to competition from Roche’s RHHBY Vabysmo. The uptake of Roche’s Vabysmo has been phenomenal. Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A.\nBiosimilar competition for Eylea is also worrisome.\nTo counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose, it now seems Eylea HD will take some time to offset the rapid erosion in Eylea sales.\nRegeneron has a collaboration agreement with Bayer BAYRY for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea’s sales outside the United States.\nDupixent Boosts REGN’s Top Line\nThe company’s top line benefits from its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi SNY records global net product sales of Dupixent.\nSolid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line for both Sanofi and Regeneron.\nSNY and REGN are working to expand the drug’s label further. The FDA recently approved Dupixent for chronic obstructive pulmonary disease (COPD). The approved indication is an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype.\nLast month, the European Commission expanded Dupixent’s label to treat eosinophilic esophagitis in children as young as one year of age.\nStrong demand trends and consistent label expansion should fuel Dupixent sales.\nREGN’s Focus on Oncology\nThe company also has other arrows in its quiver. It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer.\nREGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono.\nHowever, the company’s efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued complete response letters (CRL) for its BLA for odronextamab in March 2024.\nThe FDA issued a CRL for the biologics license applicationBLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma that has progressed after at least three prior therapies. The sole approvability issue identified is related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. Resolution of this issue will be required for both FDA and EC regulatory approvals.\nEarlier, a phase II study for fianlimab, an antibody to LAG-3, in combination with Libtayo for perioperative non-small cell lung cancer, and a phase II/III study for fianlimab, in combination with Libtayo for perioperative melanoma, were also initiated.\nThe successful development of these oncology drugs should be a great boost for REGN.\nREGN: Valuation & Estimates\nGoing by the price/earnings ratio, REGN shares currently trade at 19.49 forward earnings, higher than its mean of 19.24 and the large-cap pharma industry’s 16.62.\nImage Source: Zacks Investment Research\nThe Zacks Consensus Estimate for 2024 earnings per share has risen 55 cents to $45.14 over the past 60 days.\nImage Source: Zacks Investment Research\nConclusion\nLarge biotech companies are considered safe havens for investors interested in this sector.\nRegeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United States District Court for the Northern District of West Virginia related to a biosimilar of its Eylea.\nThe FDA also approved Amgen’s biosimilar of Eylea — Pavblu.  This is the fifth biosimilar approved for Eylea.\nWhile Regeneron has solid long-term growth prospects, the near-term pipeline setbacks and biosimilar challenges with Eylea are a concern for now. We would advise investors to wait and watch for the time being. For investors already owning the stock, staying invested at current levels will be prudent.\nREGN currently carries a Zacks Rank #3 (Hold).  You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRegeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report\nSanofi (SNY) : Free Stock Analysis Report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nBayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491537198"}